Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01853644 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Epithelial Ovarian Cancer
Recurrent Fallopian Tube Cancer
Recurrent Primary Peritoneal Cancer

Interventions

DRUG: Tivozanib

Sponsor

Northwestern University

Collaborators

[object Object]